FY2027 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Leerink Partnrs increased their FY2027 earnings estimates for REGENXBIO in a report released on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings per share of ($1.25) for the year, up from their previous forecast of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

Several other research firms have also issued reports on RGNX. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. Barclays dropped their price objective on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Finally, HC Wainwright dropped their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Stock Down 4.7 %

Shares of RGNX stock opened at $9.18 on Thursday. The company’s 50 day moving average is $10.37 and its 200 day moving average is $12.14. REGENXBIO has a 52-week low of $8.53 and a 52-week high of $28.80. The firm has a market cap of $454.82 million, a price-to-earnings ratio of -1.83 and a beta of 1.23.

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This represents a 46.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.13% of the company’s stock.

Institutional Trading of REGENXBIO

Several hedge funds have recently made changes to their positions in the company. Redmile Group LLC lifted its holdings in shares of REGENXBIO by 21.0% in the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after acquiring an additional 790,866 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of REGENXBIO by 258.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after buying an additional 588,773 shares during the last quarter. Vanguard Group Inc. grew its position in shares of REGENXBIO by 9.8% in the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock valued at $102,756,000 after buying an additional 436,043 shares during the last quarter. Artal Group S.A. purchased a new position in REGENXBIO during the 1st quarter worth $5,268,000. Finally, Integral Health Asset Management LLC grew its position in REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after purchasing an additional 190,000 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.